Home
    • Plans Blog Contact
    Progyny Inc logo

    Progyny Inc

    PGNY
    Last price US$26.29
    Market cap US$2.1b
    12M price change 16.64%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    National Research CorpNRC Industry peer HealthStream IncHSTM Industry peer VEEVA SYSTEMS INCVEEV Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Progyny Inc Overview

    Industry: Health Information Services

    Sector: Healthcare

    Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York. Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Progyny Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 06, 2026

    Quarterly result summary

    Revenue was $350.5M (reported); EPS was $2 (reported).

    Revenue $350.5M reported
    EPS $2 reported
    Net income/share $0.36 reported
    Operating income $40M +64% YoY

    What changed

    • Revenue reported to $350.5M; EPS reported to $2.
    • Operating income +64% YoY to $40M.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q Aug 07, 2026 SEC filing 8-K Aug 06, 2026 Earnings material Earnings release Aug 06, 2026 SEC filing 10-Q May 08, 2026 SEC filing 8-K May 07, 2026 Earnings material Earnings release May 07, 2026 Earnings release Earnings release May 07, 2026 SEC filing 10-K Feb 27, 2026 Earnings material Earnings release Feb 26, 2026 SEC filing 8-K Feb 26, 2026 Earnings release Earnings release Feb 26, 2026

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 3.00/5
    Progyny Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Health Information Services industry , National Research Corp , HealthStream Inc , VEEVA SYSTEMS INC are companies with high ratings.

    Return on Equity

    Score 2.40/5
    Progyny Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Progyny Inc PGNY US$2.1b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 3.55/5
    Progyny Inc commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Progyny Inc PGNY US$2.1b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Health Information Services industry , National Research Corp , HealthStream Inc , VEEVA SYSTEMS INC are companies with high ratings.

    Leverage

    Score 2.76/5
    Progyny Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Progyny Inc PGNY US$2.1b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Progyny Inc logo

    Progyny Inc

    US$26.29

    US$41.26

    +57.0% vs price

    US$2.1b

    -6.54%

    16.64%